ReviewFrontiers in medicine2025
Biomarkers to predict the severity of acute pancreatitis.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Spexin as a Novel Biomarker for Predicting Disease Severity and Mortality in Acute Pancreatitis.International journal of molecular sciences · 2026Article
- Multisystem laboratory changes before and after blood purification in acute pancreatitis: a real-world descriptive analysis of 141 cases.Frontiers in medicine · 2026Article
- Spatiotemporal Heterogeneity of Macrophages in Acute Pancreatitis: From Inflammatory Initiators to Repair Coordinators and Targeted Therapeutics.Mediators of inflammation · 2026Review
- Post-translational modification crosstalk in acute pancreatitis: linking acinar stress to innate immune amplification and tissue repair.Frontiers in immunology · 2026Review
- Long non-coding RNA AC245100.4 for early diagnosis and prognostic assessment in acute pancreatitis: clinical value and inflammation-regulatory mechanisms.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pancreatitis (AP) is pancreatic inflammation caused by abnormal activation of trypsinogen, and moderately severe or severe acute pancreatitis (SAP) can lead to systemic inflammatory response syndrome (SIRS) and organ failure, associated with high mortality. Therefore, early prediction of the severity of acute pancreatitis is particularly important to improve patient survival rate and reduce complications. Currently, many scoring systems (e.g., Ranson scoring, etc) and classical biomarkers are available in the clinical practice, but there are still many limitations, such as low predictive value and time delay. Potential biomarkers for the prediction of SAP are still a hot topic in current research. In this review, we aim to summarize newly discovered biomarkers for the prediction of the severity of acute pancreatitis in the recent years, and provide an overview of serum markers, intestinal flora, and genetic markers. At the same time, the development of emerging detection technologies [e.g., Robust AP Identification and Diagnosis (RAPIDx) and droplet digital PCR (ddPCR)] also provides new possibilities for early prediction of SAP, allowing these biomarkers to be applied clinically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.